Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
35,033
archived clinical trials in
Lung Cancer

GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Non-Small Cell Lung Cancer
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Resectable MAGE-A3 Positive Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  12/31/1969
249
mi
from 02139
Langhorne, PA
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Non-Small Cell Lung Cancer
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Resectable MAGE-A3 Positive Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
249
mi
from 02139
Langhorne, PA
Click here to add this to my saved trials
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Non-Small Cell Lung Cancer
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Resectable MAGE-A3 Positive Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  12/31/1969
270
mi
from 02139
Philadelphia, PA
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Non-Small Cell Lung Cancer
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Resectable MAGE-A3 Positive Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
270
mi
from 02139
Philadelphia, PA
Click here to add this to my saved trials
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Non-Small Cell Lung Cancer
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Resectable MAGE-A3 Positive Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  12/31/1969
477
mi
from 02139
Pittsburgh, PA
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Non-Small Cell Lung Cancer
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Resectable MAGE-A3 Positive Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
477
mi
from 02139
Pittsburgh, PA
Click here to add this to my saved trials
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Non-Small Cell Lung Cancer
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Resectable MAGE-A3 Positive Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  12/31/1969
278
mi
from 02139
Sayre, PA
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Non-Small Cell Lung Cancer
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Resectable MAGE-A3 Positive Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
278
mi
from 02139
Sayre, PA
Click here to add this to my saved trials
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Non-Small Cell Lung Cancer
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Resectable MAGE-A3 Positive Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  12/31/1969
257
mi
from 02139
Wilkes-Barre, PA
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Non-Small Cell Lung Cancer
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Resectable MAGE-A3 Positive Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
257
mi
from 02139
Wilkes-Barre, PA
Click here to add this to my saved trials
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Non-Small Cell Lung Cancer
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Resectable MAGE-A3 Positive Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  12/31/1969
413
mi
from 02139
Willow Grove, PA
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Non-Small Cell Lung Cancer
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Resectable MAGE-A3 Positive Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
413
mi
from 02139
Willow Grove, PA
Click here to add this to my saved trials
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Non-Small Cell Lung Cancer
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Resectable MAGE-A3 Positive Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  12/31/1969
40
mi
from 02139
Providence, RI
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Non-Small Cell Lung Cancer
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Resectable MAGE-A3 Positive Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
40
mi
from 02139
Providence, RI
Click here to add this to my saved trials
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Non-Small Cell Lung Cancer
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Resectable MAGE-A3 Positive Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  12/31/1969
819
mi
from 02139
Charleston, SC
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Non-Small Cell Lung Cancer
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Resectable MAGE-A3 Positive Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
819
mi
from 02139
Charleston, SC
Click here to add this to my saved trials
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Non-Small Cell Lung Cancer
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Resectable MAGE-A3 Positive Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  12/31/1969
783
mi
from 02139
Columbia, SC
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Non-Small Cell Lung Cancer
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Resectable MAGE-A3 Positive Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
783
mi
from 02139
Columbia, SC
Click here to add this to my saved trials
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Non-Small Cell Lung Cancer
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Resectable MAGE-A3 Positive Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  12/31/1969
795
mi
from 02139
Greenville, SC
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Non-Small Cell Lung Cancer
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Resectable MAGE-A3 Positive Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
795
mi
from 02139
Greenville, SC
Click here to add this to my saved trials
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Non-Small Cell Lung Cancer
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Resectable MAGE-A3 Positive Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  12/31/1969
774
mi
from 02139
Spartanburg, SC
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Non-Small Cell Lung Cancer
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Resectable MAGE-A3 Positive Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
774
mi
from 02139
Spartanburg, SC
Click here to add this to my saved trials
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Non-Small Cell Lung Cancer
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Resectable MAGE-A3 Positive Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  12/31/1969
768
mi
from 02139
Sumter, SC
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Non-Small Cell Lung Cancer
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Resectable MAGE-A3 Positive Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
768
mi
from 02139
Sumter, SC
Click here to add this to my saved trials
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Non-Small Cell Lung Cancer
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Resectable MAGE-A3 Positive Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  12/31/1969
909
mi
from 02139
Chattanooga, TN
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Non-Small Cell Lung Cancer
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Resectable MAGE-A3 Positive Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
909
mi
from 02139
Chattanooga, TN
Click here to add this to my saved trials
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Non-Small Cell Lung Cancer
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Resectable MAGE-A3 Positive Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  12/31/1969
879
mi
from 02139
Cookeville, TN
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Non-Small Cell Lung Cancer
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Resectable MAGE-A3 Positive Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
879
mi
from 02139
Cookeville, TN
Click here to add this to my saved trials
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Non-Small Cell Lung Cancer
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Resectable MAGE-A3 Positive Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  12/31/1969
816
mi
from 02139
Knoxville, TN
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Non-Small Cell Lung Cancer
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Resectable MAGE-A3 Positive Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
816
mi
from 02139
Knoxville, TN
Click here to add this to my saved trials
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Non-Small Cell Lung Cancer
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Resectable MAGE-A3 Positive Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  12/31/1969
1124
mi
from 02139
Memphis, TN
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Non-Small Cell Lung Cancer
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Resectable MAGE-A3 Positive Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
1124
mi
from 02139
Memphis, TN
Click here to add this to my saved trials
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Non-Small Cell Lung Cancer
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Resectable MAGE-A3 Positive Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  12/31/1969
940
mi
from 02139
Nashville, TN
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Non-Small Cell Lung Cancer
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Resectable MAGE-A3 Positive Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
940
mi
from 02139
Nashville, TN
Click here to add this to my saved trials
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Non-Small Cell Lung Cancer
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Resectable MAGE-A3 Positive Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  12/31/1969
1719
mi
from 02139
Amarillo, TX
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Non-Small Cell Lung Cancer
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Resectable MAGE-A3 Positive Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
1719
mi
from 02139
Amarillo, TX
Click here to add this to my saved trials
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Non-Small Cell Lung Cancer
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Resectable MAGE-A3 Positive Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  12/31/1969
1541
mi
from 02139
Dallas, TX
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Non-Small Cell Lung Cancer
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Resectable MAGE-A3 Positive Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
1541
mi
from 02139
Dallas, TX
Click here to add this to my saved trials
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Non-Small Cell Lung Cancer
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Resectable MAGE-A3 Positive Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  12/31/1969
1554
mi
from 02139
Grapevine, TX
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Non-Small Cell Lung Cancer
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Resectable MAGE-A3 Positive Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
1554
mi
from 02139
Grapevine, TX
Click here to add this to my saved trials
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Non-Small Cell Lung Cancer
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Resectable MAGE-A3 Positive Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  12/31/1969
1605
mi
from 02139
Houston, TX
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Non-Small Cell Lung Cancer
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Resectable MAGE-A3 Positive Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
1605
mi
from 02139
Houston, TX
Click here to add this to my saved trials
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Non-Small Cell Lung Cancer
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Resectable MAGE-A3 Positive Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  12/31/1969
1679
mi
from 02139
Round Rock, TX
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Non-Small Cell Lung Cancer
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Resectable MAGE-A3 Positive Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
1679
mi
from 02139
Round Rock, TX
Click here to add this to my saved trials
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Non-Small Cell Lung Cancer
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Resectable MAGE-A3 Positive Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  12/31/1969
1491
mi
from 02139
Tyler, TX
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Non-Small Cell Lung Cancer
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Resectable MAGE-A3 Positive Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
1491
mi
from 02139
Tyler, TX
Click here to add this to my saved trials
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Non-Small Cell Lung Cancer
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Resectable MAGE-A3 Positive Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  12/31/1969
2086
mi
from 02139
Ogden, UT
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Non-Small Cell Lung Cancer
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Resectable MAGE-A3 Positive Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
2086
mi
from 02139
Ogden, UT
Click here to add this to my saved trials
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Non-Small Cell Lung Cancer
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Resectable MAGE-A3 Positive Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  12/31/1969
2088
mi
from 02139
Salt Lake City, UT
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Non-Small Cell Lung Cancer
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Resectable MAGE-A3 Positive Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
2088
mi
from 02139
Salt Lake City, UT
Click here to add this to my saved trials
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Non-Small Cell Lung Cancer
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Resectable MAGE-A3 Positive Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  12/31/1969
405
mi
from 02139
Fairfax, VA
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Non-Small Cell Lung Cancer
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Resectable MAGE-A3 Positive Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
405
mi
from 02139
Fairfax, VA
Click here to add this to my saved trials
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Non-Small Cell Lung Cancer
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Resectable MAGE-A3 Positive Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  12/31/1969
585
mi
from 02139
Roanoke, VA
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Non-Small Cell Lung Cancer
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Resectable MAGE-A3 Positive Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
585
mi
from 02139
Roanoke, VA
Click here to add this to my saved trials
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Non-Small Cell Lung Cancer
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Resectable MAGE-A3 Positive Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  12/31/1969
2471
mi
from 02139
Everett, WA
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Non-Small Cell Lung Cancer
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Resectable MAGE-A3 Positive Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
2471
mi
from 02139
Everett, WA
Click here to add this to my saved trials
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Non-Small Cell Lung Cancer
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Resectable MAGE-A3 Positive Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  12/31/1969
2483
mi
from 02139
Seattle, WA
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Non-Small Cell Lung Cancer
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Resectable MAGE-A3 Positive Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
2483
mi
from 02139
Seattle, WA
Click here to add this to my saved trials
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Non-Small Cell Lung Cancer
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Resectable MAGE-A3 Positive Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  12/31/1969
2257
mi
from 02139
Spokane, WA
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Non-Small Cell Lung Cancer
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Resectable MAGE-A3 Positive Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
2257
mi
from 02139
Spokane, WA
Click here to add this to my saved trials
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Non-Small Cell Lung Cancer
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Resectable MAGE-A3 Positive Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  12/31/1969
2494
mi
from 02139
Tacoma, WA
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Non-Small Cell Lung Cancer
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Resectable MAGE-A3 Positive Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
2494
mi
from 02139
Tacoma, WA
Click here to add this to my saved trials
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Non-Small Cell Lung Cancer
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Resectable MAGE-A3 Positive Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  12/31/1969
2521
mi
from 02139
Vancouver, WA
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Non-Small Cell Lung Cancer
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Resectable MAGE-A3 Positive Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
2521
mi
from 02139
Vancouver, WA
Click here to add this to my saved trials
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Non-Small Cell Lung Cancer
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Resectable MAGE-A3 Positive Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  12/31/1969
929
mi
from 02139
Madison, WI
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Non-Small Cell Lung Cancer
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Resectable MAGE-A3 Positive Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
929
mi
from 02139
Madison, WI
Click here to add this to my saved trials
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Non-Small Cell Lung Cancer
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Resectable MAGE-A3 Positive Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  12/31/1969
855
mi
from 02139
Milwaukee, WI
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Non-Small Cell Lung Cancer
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Resectable MAGE-A3 Positive Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
855
mi
from 02139
Milwaukee, WI
Click here to add this to my saved trials
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Non-Small Cell Lung Cancer
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Resectable MAGE-A3 Positive Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  12/31/1969
5378
mi
from 02139
C.a.b.a.,
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Non-Small Cell Lung Cancer
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Resectable MAGE-A3 Positive Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
5378
mi
from 02139
C.a.b.a.,
Click here to add this to my saved trials
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Non-Small Cell Lung Cancer
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Resectable MAGE-A3 Positive Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  12/31/1969
1337
mi
from 02139
Fort Smith, AR
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Non-Small Cell Lung Cancer
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Resectable MAGE-A3 Positive Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
1337
mi
from 02139
Fort Smith, AR
Click here to add this to my saved trials
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Non-Small Cell Lung Cancer
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Resectable MAGE-A3 Positive Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  12/31/1969
1122
mi
from 02139
Saint Louis Park, MN
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Non-Small Cell Lung Cancer
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Resectable MAGE-A3 Positive Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
1122
mi
from 02139
Saint Louis Park, MN
Click here to add this to my saved trials
Proton Radiotherapy for Patients With Non-Small Cell Lung Cancer (NSCLC)
Phase II Escalated/Accelerated Proton Radiotherapy for Inoperable Stage I (T1-T2, N0, M0) and Selected Stage II (T3N0M0) Non-Small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated:  12/31/1969
1
mi
from 02139
Boston, MA
Proton Radiotherapy for Patients With Non-Small Cell Lung Cancer (NSCLC)
Phase II Escalated/Accelerated Proton Radiotherapy for Inoperable Stage I (T1-T2, N0, M0) and Selected Stage II (T3N0M0) Non-Small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated: 12/31/1969
Massachusetts General Hospital
1
mi
from 02139
Boston, MA
Click here to add this to my saved trials
Proton Radiotherapy for Patients With Non-Small Cell Lung Cancer (NSCLC)
Phase II Escalated/Accelerated Proton Radiotherapy for Inoperable Stage I (T1-T2, N0, M0) and Selected Stage II (T3N0M0) Non-Small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated:  12/31/1969
1606
mi
from 02139
Houston, TX
Proton Radiotherapy for Patients With Non-Small Cell Lung Cancer (NSCLC)
Phase II Escalated/Accelerated Proton Radiotherapy for Inoperable Stage I (T1-T2, N0, M0) and Selected Stage II (T3N0M0) Non-Small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated: 12/31/1969
University of Texas M.D. Anderson Cancer Center
1606
mi
from 02139
Houston, TX
Click here to add this to my saved trials
Concurrent Proton and Chemotherapy in Locally Advanced Stage IIIA/B Non-Small Cell Lung Cancer (NSCLC)
Phase II Concurrent Proton and Chemotherapy in Locally Advanced Stage IIIA/B Non-Small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated:  12/31/1969
1606
mi
from 02139
Houston, TX
Concurrent Proton and Chemotherapy in Locally Advanced Stage IIIA/B Non-Small Cell Lung Cancer (NSCLC)
Phase II Concurrent Proton and Chemotherapy in Locally Advanced Stage IIIA/B Non-Small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated: 12/31/1969
University of Texas M.D. Anderson Cancer Center
1606
mi
from 02139
Houston, TX
Click here to add this to my saved trials
Comparison of Different Types of Surgery in Treating Patients With Stage IA Non-Small Cell Lung Cancer
A Phase III Randomized Trial of Lobectomy Versus Sublobar Resection for Small (≤ 2 cm) Peripheral Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  12/31/1969
1256
mi
from 02139
Little Rock, AR
Comparison of Different Types of Surgery in Treating Patients With Stage IA Non-Small Cell Lung Cancer
A Phase III Randomized Trial of Lobectomy Versus Sublobar Resection for Small (≤ 2 cm) Peripheral Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 12/31/1969
University of Arkansas for Medical Sciences
1256
mi
from 02139
Little Rock, AR
Click here to add this to my saved trials
Comparison of Different Types of Surgery in Treating Patients With Stage IA Non-Small Cell Lung Cancer
A Phase III Randomized Trial of Lobectomy Versus Sublobar Resection for Small (≤ 2 cm) Peripheral Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  12/31/1969
1755
mi
from 02139
Aurora, CO
Comparison of Different Types of Surgery in Treating Patients With Stage IA Non-Small Cell Lung Cancer
A Phase III Randomized Trial of Lobectomy Versus Sublobar Resection for Small (≤ 2 cm) Peripheral Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 12/31/1969
University of Colorado Cancer Center - Anschutz Cancer Pavilion
1755
mi
from 02139
Aurora, CO
Click here to add this to my saved trials
Comparison of Different Types of Surgery in Treating Patients With Stage IA Non-Small Cell Lung Cancer
A Phase III Randomized Trial of Lobectomy Versus Sublobar Resection for Small (≤ 2 cm) Peripheral Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  12/31/1969
325
mi
from 02139
Lewes, DE
Comparison of Different Types of Surgery in Treating Patients With Stage IA Non-Small Cell Lung Cancer
A Phase III Randomized Trial of Lobectomy Versus Sublobar Resection for Small (≤ 2 cm) Peripheral Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 12/31/1969
Beebe Medical Center
325
mi
from 02139
Lewes, DE
Click here to add this to my saved trials
Comparison of Different Types of Surgery in Treating Patients With Stage IA Non-Small Cell Lung Cancer
A Phase III Randomized Trial of Lobectomy Versus Sublobar Resection for Small (≤ 2 cm) Peripheral Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  12/31/1969
305
mi
from 02139
Newark, DE
Comparison of Different Types of Surgery in Treating Patients With Stage IA Non-Small Cell Lung Cancer
A Phase III Randomized Trial of Lobectomy Versus Sublobar Resection for Small (≤ 2 cm) Peripheral Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 12/31/1969
Christiana Care Health System - Christiana Hospital
305
mi
from 02139
Newark, DE
Click here to add this to my saved trials
Comparison of Different Types of Surgery in Treating Patients With Stage IA Non-Small Cell Lung Cancer
A Phase III Randomized Trial of Lobectomy Versus Sublobar Resection for Small (≤ 2 cm) Peripheral Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  12/31/1969
2252
mi
from 02139
Boise, ID
Comparison of Different Types of Surgery in Treating Patients With Stage IA Non-Small Cell Lung Cancer
A Phase III Randomized Trial of Lobectomy Versus Sublobar Resection for Small (≤ 2 cm) Peripheral Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 12/31/1969
Saint Alphonsus Cancer Care Center-Boise
2252
mi
from 02139
Boise, ID
Click here to add this to my saved trials
Comparison of Different Types of Surgery in Treating Patients With Stage IA Non-Small Cell Lung Cancer
A Phase III Randomized Trial of Lobectomy Versus Sublobar Resection for Small (≤ 2 cm) Peripheral Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  12/31/1969
802
mi
from 02139
Indianapolis, IN
Comparison of Different Types of Surgery in Treating Patients With Stage IA Non-Small Cell Lung Cancer
A Phase III Randomized Trial of Lobectomy Versus Sublobar Resection for Small (≤ 2 cm) Peripheral Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 12/31/1969
Indiana University Melvin and Bren Simon Cancer Center
802
mi
from 02139
Indianapolis, IN
Click here to add this to my saved trials
Comparison of Different Types of Surgery in Treating Patients With Stage IA Non-Small Cell Lung Cancer
A Phase III Randomized Trial of Lobectomy Versus Sublobar Resection for Small (≤ 2 cm) Peripheral Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  12/31/1969
802
mi
from 02139
Indianapolis, IN
Comparison of Different Types of Surgery in Treating Patients With Stage IA Non-Small Cell Lung Cancer
A Phase III Randomized Trial of Lobectomy Versus Sublobar Resection for Small (≤ 2 cm) Peripheral Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 12/31/1969
Richard L. Roudebush Veterans Affairs Medical Center
802
mi
from 02139
Indianapolis, IN
Click here to add this to my saved trials
Comparison of Different Types of Surgery in Treating Patients With Stage IA Non-Small Cell Lung Cancer
A Phase III Randomized Trial of Lobectomy Versus Sublobar Resection for Small (≤ 2 cm) Peripheral Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  12/31/1969
1359
mi
from 02139
New Orleans, LA
Comparison of Different Types of Surgery in Treating Patients With Stage IA Non-Small Cell Lung Cancer
A Phase III Randomized Trial of Lobectomy Versus Sublobar Resection for Small (≤ 2 cm) Peripheral Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 12/31/1969
Ochsner Medical Center Jefferson
1359
mi
from 02139
New Orleans, LA
Click here to add this to my saved trials
Comparison of Different Types of Surgery in Treating Patients With Stage IA Non-Small Cell Lung Cancer
A Phase III Randomized Trial of Lobectomy Versus Sublobar Resection for Small (≤ 2 cm) Peripheral Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  12/31/1969
387
mi
from 02139
Silver Spring, MD
Comparison of Different Types of Surgery in Treating Patients With Stage IA Non-Small Cell Lung Cancer
A Phase III Randomized Trial of Lobectomy Versus Sublobar Resection for Small (≤ 2 cm) Peripheral Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 12/31/1969
Holy Cross Hospital
387
mi
from 02139
Silver Spring, MD
Click here to add this to my saved trials
Comparison of Different Types of Surgery in Treating Patients With Stage IA Non-Small Cell Lung Cancer
A Phase III Randomized Trial of Lobectomy Versus Sublobar Resection for Small (≤ 2 cm) Peripheral Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  12/31/1969
639
mi
from 02139
Ann Arbor, MI
Comparison of Different Types of Surgery in Treating Patients With Stage IA Non-Small Cell Lung Cancer
A Phase III Randomized Trial of Lobectomy Versus Sublobar Resection for Small (≤ 2 cm) Peripheral Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 12/31/1969
Saint Joseph Mercy Hospital
639
mi
from 02139
Ann Arbor, MI
Click here to add this to my saved trials